Clinical trials: Nicotinamide
Peripheral Arterial Disease
Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral arterial disease (PAD) occurs when arteries become narrowed or hardened because of a build-up of plaque or fat deposits.
- Trial name
- NCT00687076
- Testing
- Ezetimibe, Niaspan, Statin therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Baylor College of Medicine
Hyperphosphatemia
The Effect of Oral Niacinamide on Plasma Phosphorus Levels in Peritoneal Dialysis Patients
Hyperphosphatemia is common in the peritoneal dialysis population. Current strategies are insufficient to optimize phosphorus control.
- Trial name
- NCT00508885
- Testing
- Niacinamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Sepsis - to Reduce Mortality in the Intensive Care Unit
Efficacy and Safety of Oral Nicotinamide as an Adjunctive Therapy in Patients With Sepsis
Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction.
- Trial name
- NCT07655791
- Testing
- Nicotinamide 1000 mg
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Type 2 Diabetes Mellitus, Dyslipidemia
Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment
The structural and functional alterations of high density lipoproteins (HDL) levels in type 2 diabetes (T2D) patients linked to hypertriglyceridemia, hyperglycemia, insulin resistance, inflammation and oxidation, play a major…
- Trial name
- LOWHDL (NCT02153879)
- Testing
- Fenofibrate, Niacin plus laropiprant
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies
The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide.
- Trial name
- SAHA (NCT00691210)
- Testing
- Vorinostat, Niacinamide, Etoposide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Coronary Artery Disease, Dyslipidemias
Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease
Clinical studies with statins have shown that patients that suffered a cardiovascular event have a high residual risk. Residual risk decreases with the attaining of progressive lower LDL-C levels.
- Trial name
- NCT01308203
- Testing
- Extended release niacin/laropiprant
- Where
- Argentina
- Volunteers
- 32 people
- Sponsor
- Daniel A. Siniawski
Healthy
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years.
- Trial name
- NCT05878119
- Testing
- Investigational Product - MIB 626, Standardized, progressive, high intensity, multidimensional exercise, Usual Physical Activity
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Metro International Biotech, LLC
Dyslipidemia
A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
This study will evaluate the efficacy of laropiprant (LRPT) to reduce flushing symptoms beyond 6 months and will measure the impact of withdrawal of laropiprant in patients following 20 weeks of stable maintenance therapy.
- Trial name
- NCT00961636
- Testing
- ER niacin (+) laropiprant (ERN/LRPT), Extended-release niacin (ERN)
- Volunteers
- 1,152 people
- Sponsor
- Merck Sharp & Dohme LLC
Menopause
Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause
The purpose of this study is to determine whether a short supplementation (7days) with BASIS™ increases the natural production of estradiol, measured in urinary waste.
- Trial name
- NCT04841499
- Testing
- BASIS™ (Crystalline Nicotinamide Riboside 250mg and Pterostilbene 50mg)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of South Alabama
Systemic Lupus Erythematosus (Sle)
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness.
- Trial name
- NCT06032923
- Testing
- Nicotinamide Riboside
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Down Syndrome (DS)
NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome
The aim of the study is to determine the safety and tolerability of different increasing doses of MIB-626 (a microcrystalline form of β nicotinamide mononucleotide; NMN) given daily for 28 consecutive days to adults with Down…
- Trial name
- NCT07278492
- Testing
- MIB-626
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Brigham and Women's Hospital
Chronic Renal Failure, Hemodialysis
Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
The comparison between nicotinamide and sevelamer aims to demonstrate, in chronic hemodialysed patients, the non-inferiority of nicotinamide in terms of control of the phosphatemia.
- Trial name
- NICOREN (NCT01011699)
- Testing
- nicotinamide, sevelamer, cinacalcet
- Where
- 18 sites in France
- Volunteers
- 176 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Parkinson's Disease
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
Inflammation plays a central role in Parkinson's disease. The use of anti-inflammatory drugs was found to reduce the risk of PD . Niacin may play an important role in reducing inflammation in PD.
- Trial name
- NCT03462680
- Testing
- niacin
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- VA Office of Research and Development
Vascular Diseases, Kidney Disease
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
Risk of cardiovascular diseases (CVD) is significantly elevated in patients with chronic kidney disease (CKD); however, this increased risk is only partially explained by traditional CV risk factors.
- Conditions
- Vascular Diseases, Kidney Disease, Blood Pressure, Oxidative Stress
- Trial name
- NCT04040959
- Testing
- Nicotinamide riboside
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Colorado, Denver
Birth Defect, Pregnancy Loss
B-vitamin Levels and Adverse Pregnancy Outcomes
This prospective nested case-control study aims to examine the effects of blood vitamin B levels in first-trimester pregnant women on the pregnancy outcomes
- Conditions
- Birth Defect, Pregnancy Loss, Pregnancy Complications, Pregnancy Induced Hypertension
- Trial name
- NCT05073978
- Testing
- No intervention
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Westlake University
Mitochondrial Diseases, Mitochondrial Myopathies
Nicotinamide Riboside and Mitochondrial Biogenesis
Mitochondria are important parts of the cell that are responsible for producing energy. The amount of energy they produce depends on how much energy the body needs to function and this energy production can be severely impaired…
- Conditions
- Mitochondrial Diseases, Mitochondrial Myopathies, Progressive External Ophthalmoplegia, Progressive Ophthalmoplegia
- Trial name
- NCT03432871
- Testing
- Nicotinamide Riboside
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Skin Darken
Improved Skin Whitening Outcomes Associated With Nicotinamide Fortified Consumption in 30 to 50- Year-old Women
The goal of this clinical trial is to study whether the products with nicotinamide fortified could improve skin whitening in 30 to 50-year-old women.
- Trial name
- NCT05696938
- Testing
- Wonderlab Nicotinamide Drink, Ordinary Drink
- Where
- 2 sites in China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shenzhen Precision Health Food Technology Co. Ltd.,
Increase in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)
Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)
The purpose of this study is to assess an effective single oral supplement or combination of oral supplements for increasing whole blood NAD+ levels.
- Trial name
- NCT03707652
- Testing
- Oral supplement A, Oral supplement B, Oral supplement C
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
Skin Care
A Study to Evaluate of Cosmetic Benefit of a Moisturising Cream in People With Blemish Prone Skin
This study is designed to evaluate the cosmetic benefit provided by twice daily application of a developmental moisturising cream with niacinamide for 8 weeks in healthy female participants with sensitive, oily, blemish-prone…
- Trial name
- NCT03093181
- Testing
- Washout / Standard Cleanser, Test product, Positive control cleanser
- Where
- Brazil
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Immune Thrombocytopenia, Treatment
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
To evaluate the safety and efficacy of nicotinamide adenine dinucleotide in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one…
- Trial name
- NCT06776510
- Testing
- nicotinamide adenine dinucleotid/nicotinamide mononucleotide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China